Summary
- Profile Type
- Technology offer
- POD Reference
- TOTR20240430010
- Term of Validity
- 30 April 2024 - 30 April 2025
- Company's Country
- Turkey
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A group of researchers from a reputable university in Izmir has developed an impedimetric immunosensor for Covid-19. The sensor is disposable, easy to use, cost-effective and does not require trained personnel, which has significant advantages over traditional analysis methods and allows individuals to perform tests on their own.
- Full Description
-
In the invention, in order to detect the SARS-CoV-2 virus, the spike S1 protein was targeted using a screen-printed electrode (SPE) immobilized with an S1 protein-specific capture antibody in combination with electrochemical impedance spectroscopy (EIS) technique. In the selectivity study performed in artificial saliva, the impedimetric immunosensor showed a highly selective response to the target spike S1 protein of SARS-CoV-2.
With the impedimetric-based immunosensor developed within the scope of the invention, SARS-CoV-2 protein determination can be performed in a low-cost, fast, easy-to-use, easy-to-use, suitable for bedside use, reliable and sensitive manner during patient care/on-site diagnosis. With the impedimetric-based immunosensor developed within the scope of the invention, SARS-CoV-2 S1 protein determination can be performed in a low volume of 8 μL. The invention relates to the biotechnology sector for diagnostic kits. Furthermore, by developing the integration of the biosensor system developed based on the impedimetric method into handheld devices, our immunoassay procedure will be easily adaptable for the development of a portable point-of-care testing system that can be used in possible future pandemics.
Following the development of the integration of the inventive method into the handheld device at the diagnostic kit application stage, it will create potential for the development and application of impedimetric immunosensors that are handheld, easy to apply and suitable for bedside/field use in the diagnosis and monitoring of SARS-CoV-2. This will enable reliable, sensitive and selective detection of SARS-CoV-2 compared to currently known methods. The immunosensor based on the impedimetric-based method developed within the scope of the invention is at TRL 4 level and prototype development was carried out at laboratory level. It can be said that the developed immunosensor is commercially viable. In this context, the company is looking for commercial agreements with technical assistance with route-to-market companies in the biotechnology, medical, biomedical and engineering sectors.
With the immunosensor based on the developed impedimetric method, it aims to establish numerous partnerships and license agreements in various biotechnology, medical, biomedical and engineering sectors globally. In this way, with the developed impedimetric method-based immunosensor, SARS-CoV-2 protein determination will be performed in the market in a low-cost, fast, easy-to-use, suitable for bedside use, reliable and sensitive manner during patient care/on-site diagnosis. Following partnerships with stakeholders from different sectors, we will work with path-to-market partners to adapt the process to optimize the efficacy of the developed product. As part of the ongoing international growth strategy, new partners are being sought abroad with the immunosensor based on the impedimetric method developed within the scope of the invention. In this context, it is aimed to enter and collaborate with stakeholders from countries such as the United States, Germany and Switzerland. Partnerships are sought through a commercial agreement with technical assistance, including licensing opportunities. - Advantages and Innovations
-
With the immunosensor based on the impedimetric-based method developed within the scope of the invention, SARS-CoV-2 protein determination can be performed in a low-cost, fast, easy-to-use, suitable for bedside use, reliable and sensitive manner during patient care / on-site diagnosis.
Following the development of the integration of the method subject to the invention into the handheld device at the stage of application of the method subject to the invention to the diagnostic kit, it will create potential in the development and application of impedimetric immunosensors that are handheld, easy to apply and suitable for bedside / field use in the diagnosis and monitoring of SARS-CoV-2.
In addition, the immunosensor based on the impedimetric method developed within the scope of the invention has an application in artificial saliva. In this context, it is possible to perform SARS-CoV-2 protein determination by non-invasive method. With the impedimetric-based immunosensor developed within the scope of the invention, SARS-CoV-2 S1 protein determination can be performed in a low volume of 8 μL. - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
- Expected partner is a private sector company expert in diagnostic technology. This partner is expected to license this technology through commercial agreement with technical assistance.
- Type and Size of Partner
- SME 11-49SME 50 - 249SME <=10Big company
- Type of partnership
- Commercial agreement with technical assistance
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 06001012 - Medical Research06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001001 - Diagnostic services05001007 - Other diagnostic05001002 - In-vitro diagnostics
- Targeted countries
- All countries